Home » BMS Receives FDA Breakthrough Designation for Daclatasvir Dual Regimen
BMS Receives FDA Breakthrough Designation for Daclatasvir Dual Regimen
Bristol-Myers Squibb says the FDA has designated its investigational combination of daclatasvir and asunaprevir a breakthrough therapy to treat certain hepatitis C patients.
MarketWatch
MarketWatch
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May